The heart and vascular system in dialysis

The Lancet

Volumn 388, Issue 10041, 2016, Pages 276-284

  Wanner, Christoph ^a   Amann, Kerstin ^b   Shoji, Tetsuo ^c  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CARVEDILOL; EZETIMIBE; LISINOPRIL; SIMVASTATIN;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CORONARY ARTERY ATHEROSCLEROSIS; DIALYSIS; HEART; HEART ARREST; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; HYPOXEMIA; PRIORITY JOURNAL; REVIEW; UREMIA; VASCULAR DISEASE; ADVERSE EFFECTS; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMPLICATION; MICROVASCULATURE; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; MICROVESSELS; RENAL DIALYSIS; UREMIA;

EID: 84975456082     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30508-6     Document Type: Review

References (89)

1. 1 Kooman, JP, van der Sande, FM, Leunissen, KM, Kidney disease and aging: a reciprocal relation. Exp Gerontol, 2016 published online Feb 2. DOI:10.1016/j.exger.2016.02.003.
2. 2 Sarnak, MJ, Levey, AS, Schoolwerth, AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108 (2003), 2154–2169.
3. 3 DeJager, DJ, Grotendorst, DC, Jager, KJ, et al. Cardiovascular and noncardiovascular morality among patients starting dialysis. JAMA 302 (2009), 1782–1789.
4. 4 Foley, RN, Parfrey, PS, Sarnak, M, Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:suppl 3 (1998), S112–S119.
5. 5 Goodman, WG, Goldin, J, Kuizon, BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000), 1478–1483.
6. 6 Amann, K, Breitbach, M, Ritz, E, et al. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9 (1998), 1018–1022.
7. 7 Amann, K, Wanner, C, Ritz, E, et al. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 17 (2006), 2112–2119.
8. 8 Amann, K, Wiest, G, Zimmer, G, et al. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 42 (1992), 1079–1085.
9. 9 Buzello, M, Törnig, J, Faulhaber, J, Ehmke, H, Ritz, E, Amann, K, The (apo)E knockout mouse—a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14 (2003), 311–362.
10. 10 Amann, K, Tyralla, K, Gross, ML, et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 63 (2003), 1708–1713.
11. 11 Siedlecki, AM, Jin, X, Muslin, AJ, Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 75 (2009), 800–808.
12. 12 Dikow, R, Kihm, LP, Zeier, M, et al. Increased infarct size in uremic rats: reduced ischemia tolerance?. J Am Soc Nephrol 15 (2004), 1530–1536.
13. 13 Di Marco, GS, Kentrup, D, Reuter, S, et al. Soluble Flt-1 links microvascular disease with heart failure in CKD. Basic Res Cardiol, 110, 2015, 30.
14. 14 Ix, JH, Shlipak, MG, Brandenburg, VM, et al. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol 14 (2003), 3233–3238.
15. 15 Wetmore, JB, Broce, M, Malas, A, et al. Painless myocardial ischemia is associated with mortality in patients with chronic kidney disease. Nephron Clin Pract 122 (2012), 9–16.
16. 16 Jefferies, HJ, Virk, B, Schiller, B, et al. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 6 (2011), 1326–1332.
17. 17 Hothi, DK, Rees, L, Marek, J, et al. Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol 4 (2009), 790–797.
18. 18 Stewart, J, Kohen, A, Brouder, D, et al. Noninvasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure. Am J Physiol Heart Circ Physiol 287 (2004), H2687–H2696.
19. 19 Arismendi-Morillo, G, Fernandez-Abreu, M, Ultrastructural cutaneous microvascular pathology of young adults aged up to 50 years with chronic kidney disease and cognitive impairment. Ultrastruct Pathol 34 (2010), 214–218.
20. 20 Jacobi, J, Porst, M, Cordasic, N, et al. Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb reperfusion in rats. Kidney Int 69 (2006), 2013–2021.
21. 21 O'Hare, AM, Bertenthal, D, Shlipak, MG, et al. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 16 (2005), 514–519.
22. 22 Wiley, LA, Berkowitz, BA, Steinle, JJ, Superior cervical ganglionectomy induces changes in growth factor expression in the rat retina. Invest Ophthalmol Vis Sci 47 (2006), 439–443.
23. 23 Amann, K, Odoni, G, Benz, K, et al. Sympathetic blockade prevents the decrease in cardiac VEGF expression and capillary supply in experimental renal failure. Am J Physiol Renal Physiol 300 (2011), F105–F112.
24. 24 Di Marco, GS, Reuter, S, Hillebrand, U, et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 20 (2009), 2235–2245.
25. 25 Jacobi, JM, Tam, BY, Wu, G, et al. Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia. Circulation 110 (2004), 2424–2429.
26. 26 Flisinski, M, Brymora, A, Bartlomiejczyk, I, et al. Decreased hypoxia-inducible factor-1alpha in gastrocnemius muscle in rats with chronic kidney disease. Kidney Blood Press Res 35 (2012), 608–618.
27. 27 de Bie, MK, van Dam, B, Gaasbeek, A, et al. The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. Eur Heart J 30 (2009), 1559–1564.
28. 28 Foley, RN, Parfrey, PS, Kent, GM, et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11 (1996), 1277–1285.
29. 29 Sise, ME, Courtwright, AM, Channick, RN, Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int 84 (2013), 682–692.
30. 30 Issa, N, Krowka, MJ, Griffin, MD, et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation 86 (2008), 1384–1388.
31. 31 Pabst, S, Hammerstingl, C, Hundt, F, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One, 7, 2012, e35310.
32. 32 Zoccali, C, Benedetto, FA, Mallamaci, F, et al. Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. J Hypertens 19 (2001), 287–293.
33. 33 Zoccali, C, Mallamaci, F, Tripepi, G, Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 13 (2002), 729–733.
34. 34 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 3:suppl (2013), 1–150.
35. 35 Lindner, A, Charra, B, Sherrard, DJ, Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290 (1974), 697–701.
36. 36 Schwarz, U, Buzello, M, Ritz, E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15 (2000), 218–223.
37. 37 London, GM, Safar, ME, Pannier, B, Aortic aging in ESRD: structural, hemodynamic, and mortality implications. J Am Soc Nephrol, 2015 published online Oct 16. DOI:10.1681/ASN.2015060617.
38. 38 Paloian, NJ, Giachelli, CM, A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol 307 (2014), F891–F900.
39. 39 Soriano, S, Carmona, A, Triviño, F, et al. Endothelial damage and vascular calcification in patients with chronic kidney disease. Am J Physiol Renal Physiol 307 (2014), F1302–F1311.
40. 40 Litwin, M, Wühl, E, Jourdan, C, et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 16 (2005), 1494–1500.
41. 41 Matsui, M, Takeda, Y, Uemura, S, et al. Suppressed soluble Fms-like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease. Kidney Int 85 (2014), 393–403.
42. 42 Zoccali, C, Mallamaci, F, Tripepi, G, et al., CREED investigators. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40 (2002), 41–46.
43. 43 Levin, A, Rigatto, C, Barrett, B, et al. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant 29 (2014), 1037–1047.
44. 44 Tonelli, M, Muntner, P, Lloyd, A, et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol 24 (2013), 979–986.
45. 45 Rigatto, C, Levin, A, House, AA, Barrett, B, Carlisle, E, Fine, A, Atheroma progression in chronic kidney disease. Clin J Am Soc Nephrol 4 (2009), 291–298.
46. 46 Speer, T, Zewinger, S, Fliser, D, Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28 (2013), 2456–2463.
47. 47 Drechsler, C, Kalim, S, Wenger, JB, et al. Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. Kidney Int 87 (2015), 1201–1208.
48. 48 Berg, AH, Drechsler, C, Wenger, J, et al. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med, 5, 2013, 175ra29.
49. 49 Kopecky, C, Genser, B, Drechsler, C, et al. Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis. Clin J Am Soc Nephrol 10 (2015), 224–231.
50. 50 Zewinger, S, Drechsler, C, Kleber, ME, et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J 36 (2015), 3007–3011.
51. 51 Shoji, T, Masakane, I, Watanabe, Y, Iseki, K, Tsubakihara, Y, Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 6 (2011), 1112–1120.
52. 52 Hase, H, Tsunoda, T, Tanaka, Y, et al. Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int 70 (2006), 1142–1148.
53. 53 Joki, N, Hase, H, Nakamura, R, Yamaguchi, T, Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 12 (1997), 718–723.
54. 54 Iwasaki, M, Joki, N, Tanaka, Y, et al. Declining prevalence of coronary artery disease in incident dialysis patients over the past two decades. J Atheroscler Thromb 21 (2014), 593–604.
55. 55 Raschenberger, J, Kollerits, B, Titze, S, et al. Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: the GCKD study. Atherosclerosis 242 (2015), 529–534.
56. 56 Chang, AR, Grams, ME, Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting. Am J Kidney Dis 64 (2014), 567–573.
57. 57 Kuro-o, M, Klotho Phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 9 (2013), 650–660.
58. 58 Smith, ER, Ford, ML, Tomlinson, LA, et al. Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 25 (2014), 339–348.
59. 59 Keyzer, CA, de Borst, MH, van den Berg, E, et al. Calcification propensity and survival among renal transplant recipients. J Am Soc Nephrol 27 (2016), 239–248.
60. 60 Isakova, T, Xie, H, Yang, W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
61. 61 Grabner, A, Amaral, AP, Schramm, K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22 (2015), 1020–1032.
62. 62 Hu, MC, Shi, M, Cho, HJ, et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 26 (2015), 1290–1302.
63. 63 Kovesdy, CP, Kalantar-Zadeh, K, Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 73 (2008), 1355–1363.
64. 64 Isakova, T, Gutierrez, OM, Chang, Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20 (2009), 388–396.
65. 65 Nishizawa, Y, Shoji, T, Ishimura, E, Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia?. Am J Kidney Dis 38:suppl 1 (2001), S4–S7.
66. 66 Smith, GL, Masoudi, FA, Shlipak, MG, Renal impairment predicts long-term mortality risk after acute myocardial infarction. J Am Soc Nephrol 19 (2008), 141–150.
67. 67 Iseki, K, Fukiyama, K, Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 36 (2000), 820–825.
68. 68 Meyring-Wösten, A, Zhang, H, Ye, X, et al. Intradialytic hypoxemia and clinical outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 11 (2016), 616–625.
69. 69 Maggiore, Q, Pizzarelli, F, Santoro, A, et al., the Study Group of Thermal Balance and Vascular Stability. The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial. Am J Kidney Dis 40 (2002), 280–290.
70. 70 Odudu, A, Eldehni, MT, McCann, GP, Randomized controlled trial of individualized dialysate cooling for cardiac protection in hemodialysis patients. Clin J Am Soc Nephrol 10 (2015), 1408–1417.
71. 71 Levin, NW, Raimann, JG, Rocco, MV, Should the knowledge gained from the Frequent Hemodialysis Network (FHN) trials change dialysis practice?. Curr Opin Nephrol Hypertens 20 (2011), 577–582.
72. 72 Rocco, MV, Lockridge, RS Jr, Beck, GJ, et al. The effects of frequent nocturnal home hemodialysis: Frequent Hemodialysis Network (FHN) Trial Group. Kidney Int 80 (2011), 1080–1091.
73. 73 Obi, Y, Streja, E, Rhee, CM, et al. Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: a cohort study. Am J Kidney Dis, 2016 published online Feb 8. DOI:10.1053/j.ajkd.2016.01.008.
74. 74 Ok, E, Asci, G, Chazot, C, Ozkahya, M, Dorhout Mees, EJ, Dialysis 2. Controversies and problems of volume control and hypertension in haemodialysis. Lancet, 2016 published online May 22. DOI:10.1016/S0140-6736(16)30389-0.
75. 75 Wanner, C, Krane, V, März, W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005), 238–248.
76. 76 Fellström, BC, Jardine, AG, Schmieder, RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009), 1395–1407.
77. 77 Baigent, C, Landray, MJ, Reith, C, et al., on behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
78. 78 Silbernagel, G, Fauler, G, Genser, B, et al. Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients. J Am Coll Cardiol 65 (2015), 2291–2298.
79. 79 Shoji, T, Kakiya, R, Hayashi, T, et al. Serum n-3 and n-6 polyunsaturated fatty acid profile as an independent predictor of cardiovascular events in hemodialysis patients. Am J Kidney Dis 62 (2013), 568–576.
80. 80 Svensson, M, Schmidt, EB, Jorgensen, KA, N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 1 (2006), 780–786.
81. 81 Agarwal, R, Sinha, AD, Pappas, MK, Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 29 (2014), 672–681.
82. 82 Cice, G, Ferrara, L, Di Benedetto, A, et al. Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 37 (2001), 407–411.
83. 83 Cice, G, Ferrara, L, D'Andrea, A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41 (2003), 1438–1444.
84. 84 Chertow, GM, Block, GA, Correa-Rotter, R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 (2012), 2482–2494.
85. 85 Suki, WN, Zabaneh, R, Cangiano, JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72 (2007), 1130–1137.
86. 86 Singh, AK, Szczech, L, Tang, KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006), 2085–2098.
87. 87 Pinkau, T, Hilgers, KF, Veelken, R, et al. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease?. J Am Soc Nephrol 15 (2004), 517–523.
88. 88 Ortiz, A, Covic, A, Fliser, D, et al., for the Board of the EURECA-m Working Group of ERA-EDTA. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383 (2014), 1831–1843.
89. 89 Davison, SN, Levin, A, Moss, AH, et al. Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney Int 88 (2015), 447–459.